107 related articles for article (PubMed ID: 1349233)
1. Induction of myelo-monocytic My7 antigen (CD13) expression by interferon-alpha in basal cells of cutaneous T-cell lymphomas.
Dreno B; Fleischmann M; Valard S; Godefroy W; Bureau B; Stadler JF; Litoux P
Br J Dermatol; 1992 Apr; 126(4):320-3. PubMed ID: 1349233
[TBL] [Abstract][Full Text] [Related]
2. In vitro induction of basal keratinocyte MY7 antigen expression in cutaneous T-cell lymphoma is associated with response to interferon-alfa therapy.
Celerier P; Fleischmann M; Basset-Seguin N; Thill L; Bureau B; Litoux P; Dréno B
Arch Dermatol; 1993 Sep; 129(9):1136-40. PubMed ID: 8103318
[TBL] [Abstract][Full Text] [Related]
3. MY7 monoclonal antibody for diagnosis of cutaneous T-cell lymphoma.
Dreno B; Bureau B; Stalder JF; Litoux P
Arch Dermatol; 1990 Nov; 126(11):1454-6. PubMed ID: 2146925
[TBL] [Abstract][Full Text] [Related]
4. Keratinocyte-lymphocyte interaction in cutaneous T-cell lymphoma. Modulation of keratinocyte antigen My7 by a soluble factor produced by T lymphocytes.
Célérier P; Bureau B; Litoux P; Dréno B
Arch Dermatol; 1997 Jul; 133(7):837-40. PubMed ID: 9236521
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up in 51 patients with mycosis fungoides and Sézary syndrome treated by interferon-alfa.
Jumbou O; N'Guyen JM; Tessier MH; Legoux B; Dréno B
Br J Dermatol; 1999 Mar; 140(3):427-31. PubMed ID: 10233261
[TBL] [Abstract][Full Text] [Related]
6. Roferon-A (interferon alpha 2a) combined with Tigason (etretinate) for treatment of cutaneous T cell lymphomas.
Dréno B
Stem Cells; 1993 Jul; 11(4):269-75. PubMed ID: 8401250
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-7 receptor expression in cutaneous T-cell lymphomas.
Bagot M; Charue D; Boulland ML; Gaulard P; Revuz J; Schmitt C; Wechsler J
Br J Dermatol; 1996 Oct; 135(4):572-5. PubMed ID: 8915148
[TBL] [Abstract][Full Text] [Related]
8. Correlation of clinical responses with immunologic and morphologic characteristics in patients with cutaneous T-cell lymphoma treated with interferon alfa-2a.
Springer EA; Kuzel TM; Variakojis D; Kaul K; Rosen ST; Roenigk HH
J Am Acad Dermatol; 1993 Jul; 29(1):42-6. PubMed ID: 7686188
[TBL] [Abstract][Full Text] [Related]
9. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
10. Expression of T-follicular helper markers in sequential biopsies of progressive mycosis fungoides and other primary cutaneous T-cell lymphomas.
Bosisio FM; Cerroni L
Am J Dermatopathol; 2015 Feb; 37(2):115-21. PubMed ID: 25406852
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous T cell lymphoma: the helping hand of dendritic cells.
Edelson RL
Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563
[TBL] [Abstract][Full Text] [Related]
12. CD13 and TCR clone: markers of early mycosis fungoides.
Bernier C; Nguyen JM; Quéreux G; Renault JJ; Bureau B; Dreno B
Acta Derm Venereol; 2007; 87(2):155-9. PubMed ID: 17340024
[TBL] [Abstract][Full Text] [Related]
13. Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial.
Wollina U; Looks A; Meyer J; Knopf B; Koch HJ; Liebold K; Hipler UC
J Am Acad Dermatol; 2001 Feb; 44(2):253-60. PubMed ID: 11174383
[TBL] [Abstract][Full Text] [Related]
14. High numbers of DC-SIGN+ dendritic cells in lesional skin of cutaneous T-cell lymphoma.
Schlapbach C; Ochsenbein A; Kaelin U; Hassan AS; Hunger RE; Yawalkar N
J Am Acad Dermatol; 2010 Jun; 62(6):995-1004. PubMed ID: 20466174
[TBL] [Abstract][Full Text] [Related]
15. The treatment of 45 patients with cutaneous T-cell lymphoma with low doses of interferon-alpha 2a and etretinate.
Dréno B; Claudy A; Meynadier J; Verret JL; Souteyrand P; Ortonne JP; Kalis B; Godefroy WY; Beerblock K; Thill L
Br J Dermatol; 1991 Nov; 125(5):456-9. PubMed ID: 1751352
[TBL] [Abstract][Full Text] [Related]
16. Determination of myeloid antigen expression on childhood acute lymphoblastic leukaemia cells: discrepancies using different monoclonal antibody clones.
Firat H; Favier R; Adam M; Leverger G; Landman-Parker J; Cayre Y; Douay L
Leuk Lymphoma; 2001 Jun; 42(1-2):75-82. PubMed ID: 11699224
[TBL] [Abstract][Full Text] [Related]
17. Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas.
Vermeer MH; Tensen CP; van der Stoop PM; van Oostveen HW; Lund M; Scheper RJ; Willemze R
Arch Dermatol; 2001 Jul; 137(7):901-5. PubMed ID: 11453809
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous lymphocyte antigen expression in benign and neoplastic cutaneous B- and T-cell lymphoid infiltrates.
Magro CM; Dyrsen ME
J Cutan Pathol; 2008 Nov; 35(11):1040-9. PubMed ID: 18681860
[TBL] [Abstract][Full Text] [Related]
19. Expression of Fas and Fas-ligand in primary cutaneous T-cell lymphoma (CTCL): association between lack of Fas expression and aggressive types of CTCL.
Zoi-Toli O; Vermeer MH; De Vries E; Van Beek P; Meijer CJ; Willemze R
Br J Dermatol; 2000 Aug; 143(2):313-9. PubMed ID: 10951138
[TBL] [Abstract][Full Text] [Related]
20. Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma.
Aviles A; Neri N; Fernandez-Diez J; Silva L; Nambo MJ
Hematology; 2015 Oct; 20(9):538-42. PubMed ID: 25592781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
